DaVita (NYSE:DVA) Stock Price Expected to Rise, UBS Group Analyst Says

DaVita (NYSE:DVA) had its price target increased by investment analysts at UBS Group from $190.00 to $235.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price indicates a potential upside of 19.92% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on DVA. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Barclays set a $194.00 price objective on shares of DaVita in a research report on Thursday. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. TD Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and upped their target price for the stock from $126.00 to $220.00 in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $180.00.

DaVita Stock Performance

NYSE:DVA traded up $2.08 during trading hours on Thursday, reaching $195.96. The company’s stock had a trading volume of 1,817,573 shares, compared to its average volume of 1,016,811. The firm has a market capitalization of $13.09 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 0.55 and a beta of 0.84. The firm has a 50-day simple moving average of $152.12 and a 200-day simple moving average of $132.20. DaVita has a 1 year low of $101.00 and a 1 year high of $197.08.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 325.68%. The firm’s revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts anticipate that DaVita will post 14.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DaVita

Several hedge funds have recently bought and sold shares of DVA. Root Financial Partners LLC lifted its stake in shares of DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares in the last quarter. Elevation Wealth Partners LLC lifted its stake in shares of DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after buying an additional 165 shares in the last quarter. Caitlin John LLC bought a new position in shares of DaVita in the fourth quarter worth approximately $34,000. Sankala Group LLC bought a new position in shares of DaVita in the fourth quarter worth approximately $39,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of DaVita in the second quarter worth approximately $43,000. Institutional investors own 90.12% of the company’s stock.

Key Headlines Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 beat and guidance raise — DaVita reported adj. EPS $2.87 (vs. $2.33 est.), revenue ~$3.42B, and raised FY2026 adjusted EPS guidance to a 14.10–15.20 range; that combination is the primary catalyst for the rally. DaVita (DVA) Is Up 27.6% After Boosting 2026 EPS Guidance On Strong Q1 Results
• Positive Sentiment: Analyst upgrade and bullish commentary — A recent upgrade to Buy highlighted improved volumes, margin expansion and mid‑teens EPS growth expectations, supporting multiple expansion. DaVita: Improved Volumes And Tech In Focus (Rating Upgrade)
• Positive Sentiment: Margins and revenue strength reiterated — Coverage notes expanding margins and steady dialysis demand across the clinic network, reinforcing the quality of the beat. DaVita Stock Up Following Q1 Earnings & Revenue Beat, Margins Expand
• Positive Sentiment: Share repurchases supporting per‑share metrics — Management disclosed buybacks during the quarter and additional repurchases, which helps EPS and signals capital‑return focus. DaVita shares jump as Q1 results beat expectations and full-year outlook rises
• Neutral Sentiment: Earnings call transcript and detail — The Q1 call and transcript provide management’s color on volumes, reimbursement and cost drivers — useful for checking if the guidance raise reflects sustainable trends. DaVita (DVA) Q1 2026 Earnings Transcript
• Neutral Sentiment: Investor event scheduled — CFO and IR will speak at the BofA Healthcare Conference next week; expect additional detail and Q&A that could influence near‑term sentiment. DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference
• Neutral Sentiment: Options and trading flows — Unusually high call volume was observed around the print, signaling elevated speculative/bullish positioning that can amplify intraday moves. (Options note from trading desk data.)
• Negative Sentiment: Large institutional selling in recent quarters — Some big institutions (including reductions by Berkshire-related holdings noted in filings) trimmed positions in prior quarters; sustained selling or profit‑taking could cap gains. DaVita shares jump as Q1 results beat expectations and full-year outlook rises

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.